Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis

References

• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in Type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia Care. 2018;41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes. [cited 2019 Sep 20]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes.
   Google Scholar
• Buckley ST, Baekdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):pii:eaar7047.
   Web of Science ®Google Scholar
• Bakdal TA, Borregaard J, Donsmark M, et al. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide. Diabetes. 2017;66(suppl 1):A315.
   Google Scholar
• Aroda VR, Rosenstock J, Terauchi Y, PIONEER 1 Investigators, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Dia Care. 2019;42(9):1724–1732.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Rosenstock J, Canani LH, et al. Montanya E, for the PIONEER 2 investigators. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Dia Care. 2019;42(12):2272–2281.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, for the PIONEER 3 Investigators, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, Serusclat P, Violante R, Watada H, Davies M. PIONEER 3 investigators. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466–1480.
   PubMed Web of Science ®Google Scholar
• Pratley R, Amod A, Hoff ST, et al. PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Blicher TM, Rosenlund S, et al. PIONEER 5 investigators. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515–527.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Bain SC; PIONEER 6 investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Bode B, Mertens A, et al. PIONEER 7 investigators. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528–539.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration RYBELSUS (semaglutide) tablets, for oral use: Prescribing information. [cited 2020 Jan 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213182s000,213051s001lbl.pdf.
   Google Scholar
• Zinman B, for the Pioneer 8 investigators, Araki E; PIONEER 8 Investigators, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ. 985-P: oral semaglutide as add-on to insulin in T2D: PIONEER 8. Diabetes. 2019;68(Supplement 1):985-P.
   Google Scholar
• Yamada Y, Katagiri H, Hamamoto Y, et al. Efficacy and safety of oral semaglutide monotherapy vs placebo or liraglutide in Japanese T2D patients: PIONEER 9 trial. J Diabetes Investig. 2019;10(S1):30.
   Google Scholar
• Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide vs dulaglutide in Japanese T2D patients: the PIONEER 10 trial. J Diabetes Investig. 2019;10(S1):30.
   Google Scholar
• Nuhoho S, Gupta J, Hansen BB, et al. Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1-2 oral antidiabetics: systematic review and network meta-analysis. Diabetes Ther. 2019;10(6):2183–2199.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017.
   Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S61–S70.
   PubMedGoogle Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015;21 (Suppl 1):1–87.
   PubMed Web of Science ®Google Scholar
• Carls G, Huynh J, Tuttle E, et al. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017;8(4):863–873.
   PubMed Web of Science ®Google Scholar
• Okemah J, Peng J, Quiñones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018;35(11):1735–1745.
   PubMed Web of Science ®Google Scholar
• Hunt B, Hansen BB, Ericsson Å, et al. Evaluation of the cost per patient achieving treatment targets with oral semaglutide: a short-term cost-effectiveness analysis in the United States. Adv Ther. 2019;36(12):3483–3493.
   PubMed Web of Science ®Google Scholar
• Wilkinson L, Hunt B, Johansen P, et al. Cost of achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide versus dulaglutide in the United States. Diabetes Ther. 2018;9(3):951–961.
   PubMed Web of Science ®Google Scholar
• Johansen P, Hunt B, Iyer NN, et al. A relative cost of control analysis of once-weekly semaglutide versus exenatide extended-release and dulaglutide for bringing patients to HbA1c and weight loss treatment targets in the USA. Adv Ther. 2019;36(5):1190–1199.
   PubMed Web of Science ®Google Scholar
• Hunt B, McConnachie CC, Gamble C, et al. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States. J Med Econ. 2017;20(11):1117–1120.
   PubMed Web of Science ®Google Scholar
• Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. JMCP. 2013;19(3):237–246.
   PubMed Web of Science ®Google Scholar
• IBM Micromedex. RED BOOK. [cited 2019 Sep 30]. Available from: https://www.micromedexsolutions.com/home/dispatch.
   Google Scholar
• American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004;27(9):2262–2265.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials; 2011 [updated April 2014; cited 2019 Aug 14]. Available from: http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf.
   Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 3: heterogeneity: subgroups, meta- regression, bias and bias-adjustment; 2011. [cited 2019 Aug 14]. Available from: http://www.nicedsu.org.uk.
   Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials; 2011 [updated April 2014; cited 2019 Aug 14]. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/TSD4-Inconsistency.final_.15April2014.pdf.
   Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. Value Health. 2011;14(4):429–437.
   PubMed Web of Science ®Google Scholar
• Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2; 2009. [updated September 2009; cited 2019 Aug 14]. Available from: http://www.cochrane-handbook.org.
   Google Scholar
• Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14(1):77–82.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Giaccari A, et al. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab. 2018;20(3):541–548.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17(9):859–867.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes – 2019. Diabetes Care. 2019;42(Suppl 1):S81–S89.
   PubMedGoogle Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219–230.
   PubMed Web of Science ®Google Scholar
• Ridderstråle M, Evans LM, Jensen HH, et al. Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. Health Qual Life Outcomes. 2016;14(1):13.
   PubMedGoogle Scholar
• Pantalone KM, Misra-Hebert AD, Hobbs TM, et al. Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care. 2018;41(7):e113–e114.
   PubMed Web of Science ®Google Scholar
• Fu AZ, Sheehan JJ. Treatment intensification for patients with type 2 diabetes and poor glycaemic control. Diabetes Obes Metab. 2016;18(9):892–898.
   PubMed Web of Science ®Google Scholar
• Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes. 2017;11(1):3–12.
   PubMed Web of Science ®Google Scholar
• Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20(2):427–437.
   PubMed Web of Science ®Google Scholar
• Khunti K, Nikolajsen A, Thorsted BL, et al. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18(4):401–409.
   PubMed Web of Science ®Google Scholar